How big is the Malaysia Oral Anti-Diabetic Drug Market?

June 2023: The FDA has approved the drugs Jardiance and Synjardy to be taken by children ages 10 and older who have type 2 diabetes.
May 2022: Tirzepatide (Mounjaro) was approved for treating Type 2 diabetes in adults. Tirzepatide's FDA approval marks the first in a new class of diabetes medications: a dual GIP/GLP-1 receptor agonist.

The Malaysia Oral Anti-Diabetic Drug Market size is expected to reach USD 274 million in 2024 and grow at a CAGR of greater than 3% to reach USD 333 million by 2028. Read More

What is the current Malaysia Oral Anti-Diabetic Drug Market size?

In 2024, the Malaysia Oral Anti-Diabetic Drug Market size is expected to reach USD 274 million. Read More

Who are the key players in Malaysia Oral Anti-Diabetic Drug Market?

Astrazeneca, Astellas, Janssen, Eli Lilly and Sanofi are the major companies operating in the Malaysia Oral Anti-Diabetic Drug Market. Read More

What years does this Malaysia Oral Anti-Diabetic Drug Market cover, and what was the market size in 2023?

In 2023, the Malaysia Oral Anti-Diabetic Drug Market size was estimated at USD 265.78 million. The report covers the Malaysia Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Malaysia Oral Anti-Diabetic Drug Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Malaysia Oral Anti-Diabetic DrugCompanies

This report lists the top Malaysia Oral Anti-Diabetic Drug companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Malaysia Oral Anti-Diabetic Drug industry.